Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on December 2, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 152,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
达拉斯，2024年12月6日（全球新闻网络）—— Taysha Gene Therapies, Inc.（纳斯达克：TSHA）（Taysha或公司）是一家临床阶段的生物技术公司，专注于推进基于腺病毒（AAV）的基因疗法，以治疗中枢神经系统（CNS）严重单基因疾病。今天宣布，在2024年12月2日，Taysha董事会的薪酬委员会授予了一名新员工一个购买152,000股公司普通股的期权，作为其就业的关联奖励。该股票期权是根据Taysha Gene Therapies, Inc. 2023诱导计划授予的，作为该个人入职Taysha的诱导材料，符合纳斯达克上市规则5635(c)(4)。
The stock option has an exercise price of $3.08 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.
该股票期权的行使价格为3.08美元，等于授予日期Taysha普通股的收盘价。该股票期权的有效期为10年，将在四年内分期归属，其中25%的期权将在归属开始日期的第一个周年日归属，其余75%的期权将在接下来的36个月内按月等额归属。股票期权的归属需持续为Taysha工作的员工在每个归属日期完成。
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit
关于Taysha Gene Therapies
Taysha Gene Therapies（纳斯达克：TSHA）是一家临床阶段的生物技术公司，专注于推进基于腺病毒（AAV）的基因疗法，以治疗中枢神经系统的严重单基因疾病。其主导临床项目TSHA-102正在开发用于莱特综合征，这是一种罕见的神经发育障碍，目前尚无批准的能改变疾病基因根源的疾病修饰疗法。Taysha专注于开发变革性的药物，旨在解决严重未满足的医疗需求，显著改善患者及其护理者的生活。公司的管理团队在基因治疗开发和商业化方面拥有丰富的经验。Taysha利用这段经验、其制造过程以及经过临床和商业验证的AAV9外壳，努力将治疗方案快速从实验室转化为临床应用。有关更多信息，请访问
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
公司联系:
Hayleigh Collins
董事，企业传播和投资者关系负责人
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
媒体联系人：
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
Source: Taysha Gene Therapies, Inc.
来源：Taysha Gene Therapies, Inc.
